Comparison of I-125 sources used for permanent interstitial implants.
The increase in the number of manufacturers of 125I sources used in prostate brachytherapy has generated many questions in the radiation oncology community. In this investigation, the physical and dosimetric characteristics were evaluated for the following sources listed by marketing company and source model: Nycomed-Amersham 6711 (OncoSeed), Nycomed-Amersham 6702, Mentor IoGold, UroMed Symmetra, Imagyn IsoSTAR, UroCor, (PSA, Mallincrkrodt) ProstaSeed, Syncor PharmaSeed, SourceTech Medical, (BARD) 125Implant (BrachySource), Med-Tec I-Plant, Best Medical Model 2301, DraxImage BrachySeed, and International Brachytherapy, Inc. (IBT) InterSource125. The investigation examined the differences in design, construction, and the dosimetric characteristics created from each source. The dosimetric characteristics of the new sources were compared to that of the Amersham 6711 source. Parameter studies have led to the development of a simple equation that can be used to clinically convert the standard 6711 source strength to an equivalent strength of a new source.